(Q44211603)

30 November 2017

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment (English)

1 reference

30 November 2017

1 reference

1 reference

Maximilian von Eynatten

6

object named as

Maximilian von Eynatten

1 reference

30 November 2017

Janet B McGill

1

1 reference

30 November 2017

Anthony H Barnett

2

1 reference

30 November 2017

Andrew J Lewin

3

1 reference

30 November 2017

Sanjay Patel

4

1 reference

30 November 2017

Dietmar Neubacher

5

1 reference

30 November 2017

Hans-Juergen Woerle

7

1 reference

30 November 2017

language of work or name

English

0 references

publication date

29 October 2013

1 reference

Diabetes and Vascular Disease Research

30 November 2017

1 reference

30 November 2017

11

1 reference

30 November 2017

1

1 reference

30 November 2017

34-40

1 reference

Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study

30 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Frequency of hypoglycemia and its significance in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Management of glycemia in patients with diabetes mellitus and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Managing diabetes in hemodialysis patients: observations and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Hypoglycaemia in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164113507068

21 January 2018

Identifiers

DOI

10.1177/1479164113507068

1 reference

30 November 2017

1 reference